title: Latent hypothyreosis as a clinical biomarker for therapy response under abiraterone acetate therapy.
abstract: BACKGROUND
  Abiraterone acetate (AA) is a selective oral inhibitor of Steroid-17α-Hydroxylase, for patients with castration-resistant prostate cancer. Not all patients respond to therapy, however, there are no biomarkers predicting response to AA therapy. The aim of the present study was the identification of a biomarker for patients who are likely to respond to AA therapy.
  
  
  METHODS
  We measured thyroid parameters in a collective of 30 patients before and during AA therapy. For statistical analyses, paired and unpaired t-tests were used.
  
  
  RESULTS
  During AA therapy, responders developed a significant increase in thyroid stimulating hormone (TSH) compared to non-responders (p=0.03). In the subgroup of responders, 16 out of 21 patients (76.1%) had a significant increase in TSH level (p=0.001), suggesting that TSH increase is predictive of therapy response. Non-responders showed no change in TSH level during AA therapy.
  
  
  CONCLUSIONS
  Hypothyreosis may serve as a simple predictive biomarker for therapy response under AA therapy.
authors.affiliation: Associate Professor of Urology, Department of Urology, Medical University Innsbruck, Anichstr. 35, 6020 Innsbruck, Austria. jasmin.bektic@uki.at.
authors.forename: Isabel
authors.initials: I
authors.lastname: Heidegger
authors.forename: Udo
authors.initials: U
authors.lastname: Nagele
authors.forename: Andreas
authors.initials: A
authors.lastname: Pircher
authors.forename: Renate
authors.initials: R
authors.lastname: Pichler
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Horninger
authors.forename: Jasmin
authors.initials: J
authors.lastname: Bektic
mesh_terms: D000069501:Abiraterone Acetate; D000368:Aged; D000369:Aged, 80 and over; D000730:Androstadienes / Q000009:adverse effects*; D054316:Biomarkers, Pharmacological / Q000032:analysis*; D001859:Bone Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000556:secondary; D005500:Follow-Up Studies; D006801:Humans; D007037:Hypothyroidism / Q000139:chemically induced / Q000175:diagnosis*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D013254:Steroid 17-alpha-Hydroxylase / Q000037:antagonists & inhibitors; D013972:Thyrotropin / Q000378:metabolism
chemical_list: D000730:Androstadienes; D054316:Biomarkers, Pharmacological; D013972:Thyrotropin; D013254:Steroid 17-alpha-Hydroxylase; D000069501:Abiraterone Acetate
keywords: Abiraterone acetate; biomarker; castration-resistant prostate cancer; hypothyreosis